Author: Louis Navellier and the InvestorPlace Research Staff

A rare bargain at an irrationally low valuation, now could be a prime opportunity.

It’s been in growth mode for over a decade, and its Covid-19 vaccine is going to continue to sell for the foreseeable future. Plus, the company has a solid product lineup outside of the spotlight vaccine.

It’s up 138% year-to date, but its momentum won’t run out any time soon.

There are no guarantees when it comes to the stock market… however, these stocks offer a compelling long-term growth story combined with solid fundamentals.